Fludarabine dosing study for B-cell ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tests a different dose of the chemotherapy drug fludarabine before CAR T-cell therapy (tisagenlecleucel) for children and young adults with B-cell acute lymphoblastic leukemia. The goal is to see if the new dose works better at helping the body accept the CAR T cells while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a CAR T-cell therapy called tisagenlecleucel (Kymriah) for your B-cell acute lymphoblastic leukemia.
- You weigh more than 9 kilograms (about 20 pounds).
- Your liver, kidneys, heart, and lungs are working well enough (doctors will check with blood tests and scans).
- You are generally active and able to do daily activities (doctors will ask about your energy level).
- You and your family agree to take part in the study and sign the consent forms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.